Tumor cells with donor genotype have been identified in human skin cancer after allogeneic transplantation; however, the donor contribution to the malignant epithelium has not been established. Kidney transplant recipients have an increased risk of invasive skin squamous cell carcinoma (SCC), which is associated with accumulation of the tumor suppressor p53 and TP53 mutations. In 21 skin SCCs from kidney transplant recipients, we systematically assessed p53 expression and donor/recipient origin in laser-microdissected p53+ tumor cells. In one patient, molecular analyses demonstrated that skin tumor cells had the donor genotype and harbored a TP53 mutation in codon 175. In a kidney graft biopsy performed 7 years before the skin SCC diagnosis, we found p53+ cells in the renal tubules. We identified the same TP53 mutation in these p53+ epithelial cells from the kidney transplant. These findings provide evidence for a donor epithelial cell contribution to the malignant skin epithelium in the recipient in the setting of allogeneic kidney transplantation. This finding has theoretical implications for cancer initiation and progression and clinical implications in the context of prolonged immunosuppression and longer survival of kidney transplant patients.
Human skin carcinoma arising from kidney transplant–derived tumor cells

Laurence Verneuil,1,2,3 Mariana Varna,1,4 Philippe Ratajczak,1,4 Christophe Leboeuf,1,4 Louis-François Plassa,5 Morad Elbouchtaoui,1,4,6 Pierre Schneider,1,4 Wissam Sandid,6 Celeste Lebbé,4,7 Marie-Noelle Peraldi,4,8 François Sigaux,4 Hugues de Thé,4,5 and Anne Janin1,4,6

1INSERM, U-728, Paris, France. 2Dermatology, CHU Caen, Caen, France. 3Université Caen Basse Normandie, Medical School Caen, Caen, France. 4Université Paris Diderot, Sorbonne Paris Cité, UMR-S-728, Paris, France. 5Biochemistry, 6Pathology, 7Dermatology, and 8Transplantation, AP-HP, Hôpital Saint Louis, Paris, France.

Tumor cells with donor genotype have been identified in human skin cancer after allogeneic transplantation; however, the donor contribution to the malignant epithelium has not been established. Kidney transplant recipients have an increased risk of invasive skin squamous cell carcinoma (SCC), which is associated with accumulation of the tumor suppressor p53 and TP53 mutations. In 21 skin SCCs from kidney transplant recipients, we systematically assessed p53 expression and donor/recipient origin in laser-microdissected p53+ tumor cells. In one patient, molecular analyses demonstrated that skin tumor cells had the donor genotype and harbored a TP53 mutation in codon 175. In a kidney graft biopsy performed 7 years before the skin SCC diagnosis, we found p53+ cells in the renal tubules. We identified the same TP53 mutation in these p53+ epithelial cells from the kidney transplant. These findings provide evidence for a donor epithelial cell contribution to the malignant skin epithelium in the recipient in the setting of allogeneic kidney transplantation. This finding has theoretical implications for cancer initiation and progression and clinical implications in the context of prolonged immunosuppression and longer survival of kidney transplant patients.

Introduction
The concept of adult stem cell plasticity (1, 2) has opened new fields for scientific and clinical developments. Allogeneic transplantations offer a rare clinical opportunity to study homing and in situ development of stem cells in humans. In addition, the main long-term complication of allogeneic transplantations (3) is the occurrence of cancers (4, 5). Patients with kidney transplants are at risk for skin epithelial tumors (4), which preferentially develop on sun-exposed areas (6). Accumulation of tumor-suppressing p53 is significantly associated with these squamous cell carcinomas (SCCs) (7), and TP53 mutations are found in tumor cells (8). In a series of kidney transplant recipients, tumor cells of donor genotype have been identified in 1 skin basal cell carcinoma (9), but the type of donor cell that homed to the skin remains to be characterized. In addition, there was no evidence of a donor epithelial cell contributing to the malignant epithelium in the recipient.

Systematic study of p53 expression and TP53 mutations in 21 skin SCCs from kidney transplant recipients enabled us to identify a case (referred to herein as Patient 1) with p53+ tumor cells of donor origin and a mutation on codon 175. In a kidney graft biopsy performed on Patient 1 7 years before the skin SCC diagnosis, we found p53+ cells in the renal tubules. We therefore performed laser microdissection of p53+ tumor cells from these areas that coexpressed the cytokeratin AE1/AE3 (Figure 1A), in order to select representative material for further molecular study.

Results and Discussion
21 kidney transplant patients diagnosed with skin SCC between 2000 and 2007 in the same university hospital had a minimum 5-year follow-up. For this study, SCC histological diagnosis was independently reviewed by 2 pathologists. As expected in organ transplant recipients, SCCs occurred after a long immunosuppression period (mean, 10.55 years; range, 3–21 years) and on sun-exposed areas (3, 6). Systematic p53 analyses showed that all SCCs strongly expressed p53 in the tumor cells. In nonlesional sun-exposed areas, skin basal cells weakly expressed p53. In SCC, p53 expression also predominated in the basal layer, particularly at sites of dermal invasion (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI66721DS1). We therefore performed laser microdissection of p53+ tumor cells from these areas that coexpressed the cytokeratin AE1/AE3 (Figure 1A), in order to select representative material for genetic analyses (10).

Tumor cell origin was studied on DNA extracted from laser-microdissected p53+ tumor cells, using mitochondrial DNA–high-resolution melting (mtDNA-HRM) and polymorphic microsatellite markers. 2 female patients with previous male pregnancies were excluded from this study. The 2 molecular methods used gave interpretable results in 14 of the remaining 19 patients.

In Patient 1, mtDNA-HRM showed that laser-microdissected p53+ tumor cells had curves similar to the donor curves and different from the recipient curves (Figure 1B). Since widespread heterogeneity (heteroplasmy) has been found in normal and cancer cell mtDNA in humans (11), we checked our HRM results using Sanger sequencing: no heteroplasmy was detected. We next studied 7 polymorphic microsatellite markers for their informative value, showing different donor and recipient profiles. Of these, 3 (D8S1820, D17S1879, and D3S3611) again clearly established the donor-derived origin of the skin SCC (Figure 1C). In all, 12 of the 14 patients with interpretable molecular results had a SCC of recipient origin, and 2 had a SCC with presence of donor cells.

A donor-derived malignant proliferation after allogeneic transplantation was first identified in 1971, in a leukemia of donor ori-
gin after bone marrow transplantation (12). More than 50 cases have since been reported and are considered to result from oncogenic transformation of apparently normal donor hematopoietic cells in the transplant recipient (12). More surprising was the identification of a donor-derived genotype in epithelial cells in 4 cases of oral SCC after bone marrow transplantation (13), because this implied that donor-derived bone marrow cells, either hematopoietic or mesenchymal, yielded epithelial tumors. Donor-derived cells were also found in a skin basal cell carcinoma in a kidney transplant recipient (9), but the donor cell contribution to the malignant epithelium was not established.

The skin carcinoma in Patient 1 was, as in a large series of kidney transplant recipients, a SCC (3, 6) that occurred in UV-exposed areas (4, 6) and expressed p53 (7). The predominance of SCC, a fully differentiated type of skin carcinoma, over basal cell carcinoma in kidney transplant recipients contrasts with the predominance of basal cell carcinoma in the general population (3, 4). The specific distribution of SCC in UV-exposed areas could be linked to UV-induced keratinocyte damage, an event able to trigger stem cell mobilization in the skin (14). In addition, the role of UV-induced TP53 mutations in skin SCC has long been established (15). More than 10 TP53 mutations in skin SCC in kidney transplant recipients have been characterized (8), including the UV-specific tandem CC>TT, a mutation more linked to the UVA effect in the epidermal basal layer (16).

In the 2 patients with donor-derived p53<sup>+</sup> cells in their skin SCC, PCR-HRM screening was performed to compare DNA from microdissected p53<sup>+</sup> tumor cells and a control DNA, including a wild-type TP53 gene. In Patient 1, PCR-HRM screening showed a shift fragment for exons 5–8 of TP53. Sequencing of this shift fragment identified a G>A base substitution on codon 175, corresponding to a R>H amino acid change in DNA, from laser-microdissected p53<sup>+</sup> tumor cells.

Figure 1
Recipient skin SCC. (A) Laser microdissection of p53<sup>+</sup>AE1/AE3<sup>+</sup> basal cells from invasive areas. Scale bars: 15 μm. (B) mtDNA-HRM of laser-microdissected p53<sup>+</sup> tumor cells and donor and recipient normal cells. Laser-microdissected p53<sup>+</sup> tumor cells and donor normal cells showed similar profiles. (C) DNA profiles from laser-microdissected p53<sup>+</sup> tumor cells and donor and recipient normal cells. Microsatellite analysis at the D8S1820 locus showed the donor origin of the p53<sup>+</sup> tumor cells (106 and 114 bp), similar to donor DNA, but different from recipient DNA (106 and 112 bp). At the D17S1879 locus, microdissected p53<sup>+</sup> tumor cell and donor DNA were heterozygous (155 and 159 bp), but recipient DNA was homozygous (155 bp). (D) Sequencing of TP53 exon 5 PCR product identified a base substitution G>A on codon 175, corresponding to a R>H amino acid change in DNA, from laser-microdissected p53<sup>+</sup> tumor cells.
sequencing showed that the TP53 mutation in p53+ cells from both kidney tubules and skin SCC was not heterozygous. We therefore used a different molecular method to check this result. A study of the polymorphic microsatellite marker IGP53, located in intron 1 of TP53, was performed to compare the profiles of the donor and the microdissected p53+ cells from skin SCC and from kidney graft tubules. This demonstrated a loss of heterozygosity in the skin SCC and kidney graft tubule microdissected cells (Figure 2C).

In the case of Patient 1, these TP53 changes were not linked to a cancer predisposition (Li-Fraumeni syndrome) (18), since there was no family history of cancer under 45 years, and this patient had no other cancer than his skin cancer.

We thus provided evidence of a donor renal epithelial cell contribution to the malignant epithelium in the recipient skin SCC. In adult human kidney, different types of progenitor cells have been characterized in tubules. Cells with a CD133+CD24+CD106− phenotype are committed toward tubular lineage (19). In Patient 1, p53+CD24+ cells were found in tubules in the kidney biopsy (Figure 2D and Supplemental Methods). In addition, TP53 expression increases in kidney allografts when cold ischemia is prolonged beyond 24 hours, a common time lapse when kidneys from deceased donors are transplanted (20), as in Patient 1. Different TP53 mutations have been reported in renal carcinomas, including mutations in exons 5–8, where we found the codon 175 mutation.

Our finding of an identical TP53 mutation in the p53+ cells in the tubular epithelium from the kidney graft and in tumor cells from the recipient skin SCC demonstrated a contribution of donor cells to the recipient malignant epithelium. However, the question remains why, in the 7-year follow-up, Patient 1 developed a carcinoma in the skin and not in the grafted kidney. This could be explained by additional oncogenic events in the recipient skin. Extended genomic analysis via the molecular inversion probe-based genotyping system enabled us to detect a KRAS mutation in the skin SCC (Supplemental Figure 3). However, we used a specific KRAS probe to perform PCR analysis and did not detect this mutation in the kidney biopsy (Supplemental Methods). RAS mutations have been recently identified in skin SCC in patients treated with BRAF inhibitors (21). This was not the case for Patient 1. Apart from the KRAS mutation, UV radiation could also instigate additional oncogenic events in the recipient skin. In this patient, a deleterious synergistic effect between UV and azathioprine could have occurred, since azathioprine causes 6-thioguanine accumula-
tion in patient DNA and, in cell cultures, 6-thioguanine and UVA are synergistically mutagenic (22). Our results provide the first evidence for donor contribution to the malignant epithelium of skin SCC in a kidney transplant recipient. This finding has theoretical implications for the model of cancer initiation and/or progression as well as clinical implications in the context of prolonged immunosuppression and longer survival of kidney transplant patients.

Methods

Patients and samples. From 2000 to 2007, skin SCC were diagnosed in 21 kidney transplant recipients who had available archival samples and donor and recipient DNA. Patients had received kidneys from deceased donors for extramembranous glomerulonephritis, malformative urethra, or Henoch-Schönlein purpura. After kidney transplantation, immunosuppression included corticosteroids, tacrolimus, mycophenolate-mofetil, cyclosporine, and azathioprine. All biopsy samples, taken for diagnostic purposes, had been formalin fixed and paraffin embedded. SCC histological diagnosis was reviewed by 2 pathologists. From samples remaining after diagnosis had been established, sister sections were subsequently taken from each block.

p53 immunostaining and laser microdissection of skin p53+AE1/AE3+ tumor cells. p53 immunostaining was performed on 5-μm-thick skin SCC sections using indirect immunoperoxidase staining, with anti-human p53 mouse antibody (clone DO7, Dako). Skin SCC areas with strong p53 expression in basal layers and invasive areas were selected, and 7-μm-thick paraffin sections from the corresponding tissue blocks were spread on membrane-coated slides. Double immunostaining was then performed using anti-p53 antibody with immunoperoxidase staining and anti-cytokeratin antibody (clone AE1/AE3, an epithelial marker, Roche Diagnostics) with FITC staining. Using a PALM-Microbeam/Zeiss system, laser microdissection was performed on p53+AE1/AE3+ cells in invasive areas of skin SCC with a pulsed UV-A nitrogen laser (337 nm), used to cut and catapult microdissected cells directly into the buffer-containing cap of a microfuge tube. At least 1,000 p53+ tumor cells were laser microdissected, and DNA was extracted using a QiaGen kit. DNA quality was checked by spectrophotometry assay (Nanodrop 1000, Thermo Scientific). The cell population selected by laser microdissection was checked using quantitative RT-PCR (qRT-PCR) on an ABI PRISM 7700 system and predeveloped TaqMan assay reagents specific to KRT14 (Hs00265033_m1) and PTPRC (Hs00365634_g1). Laser-microdissected cells expressed KRT14 mRNA, an epithelial marker, and not PTPRC mRNA, a pan-leucocyte marker.

mtDNA-HRM analyses of microdissected p53+ tumor cells. mtDNA profiles from SCC laser-microdissected p53+ tumor cells were compared with those from donor and recipient cells. Primers were designed to flank the hyper-variable regions I of the noncoding displacement loop (D-loop) of mtDNA from NCBI reference sequence NC_012920.1 (23), and synthesized (Eurogentec). Primers flanking the hypervariable regions I were used to amplify an initial 243-bp PCR product using the forward primer 16105F (5′-TGGCCACCCAGATGTA-3′) and reverse primer 16348R (5′-GACTGTAATGGCTGCTATGACCTGAATA-3′). See Supplemental Methods for PCR cycling, mix, and HRM steps. All reactions were completed in triplicate.


